LA

Latin American Cooperative Oncology Group at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Latin American Cooperative Oncology Group takes part in 5 sessions at ESMO 2026 in Madrid. Its program centres on breast cancer, especially metastatic disease, treatment choices in hormone receptor-positive, HER2-negative disease and antibody-drug conjugates in breast and gynaecological cancers. It presents quality-of-life results comparing trastuzumab deruxtecan with trastuzumab emtansine in high-risk HER2-positive early breast cancer.

OrganizationESMO 2026 Attendance
LA
Latin American Cooperative Oncology Group
Porto Alegre, Brazil
Society & non-profit
Nonprofit academic cooperative group that designs and runs cancer clinical trials across Latin America, based in Porto Alegre, Brazil.
Talk
Sat Oct 24
16:30–16:45
How can we incorporate combination strategies in early drug development?
Novel concepts for metastatic breast cancer: Looking to the future
Breast cancerBiomarkers & precision oncology
Chair
Sat Oct 24
16:30–18:00
Novel concepts for metastatic breast cancer: Looking to the future
with Peter MacCallum Cancer Centre
Breast cancerBiomarkers & precision oncology
Satellite
Sat Oct 24
18:55–19:05
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute
Breast cancer
Satellite
Sat Oct 24
19:05–19:20
Rethinking Metastatic Breast Cancer: Endocrine Sensitivity, Biomarkers, and the Role of
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction
Breast cancer
Satellite
Sat Oct 24
19:20–19:30
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute
Breast cancer
Satellite
Sat Oct 24
19:40–19:50
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute
Breast cancer
Talk
Sun Oct 25
10:15–10:45
Metastatic breast cancer: Case presentation & Discussion
ESMO Clinical Practice Guidelines 2 · with Sestre milosrdnice University Hospital Centre
Breast cancerGenitourinary cancers
Satellite
Sun Oct 25
18:30–18:35
Welcome and Introduction
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions
Breast cancerGynaecological cancers
Satellite
Sun Oct 25
18:35–19:00
Clinical Foundation: Building and Broadening the Role of ADCs in Metastatic Breast Cancer
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions
Breast cancerGynaecological cancers
Satellite
Sun Oct 25
19:45–20:00
Connecting Experience, Potential, and Future Frontiers: Panel discussion and audience Q&A
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions · with University of California San Diego, University Hospitals Leuven
Breast cancerGynaecological cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Latin American Cooperative Oncology Group

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction